DAY ONE - Wednesday October 2

8:00 am Check-In & Light Breakfast

8:50 am Chair’s Opening Remarks

The Future of RNA Delivery: Illuminating Next Generation Non-Viral Delivery Vehicles Beyond LNPs for Greater Biological & Commercial Success

9:00 am Expert Panel Discussion – De-Risking RNA Delivery Platforms Through Uncovering the Most Suitable Platforms for Your RNA Payloads to Ensure Effective Treatment

Synopsis

  • With an array of nonviral delivery carriers in development, how do you identify which is the most suitable method for your RNA therapeutic?
  • How can the field leverage and learn from approved carriers, such as LNPs, to overcome 2024 IP complexities?
  • When developing a novel delivery vehicle, how is the field de-risking their platforms to ensure a commercial success given the crowded IP landscape?

10:00 am RNABL: A Polyester Dendrimer-Based Platform for Therapeutic RNA Delivery

Synopsis

  • RNABL dendrimers are a class of molecularly defined highly branched biodegradable molecules with lower reactogenicity and better safety characteristics
  • RNABL nanoparticles displayed improved characteristics compared to other non-viral nucleic acid delivery platforms tested
  • Structural modifications of RNABL delivery materials resulted in organ-specific nucleic acid delivery (e.g. lungs, spleen, heart)

10:30 am Morning Break & Speed Networking

Synopsis

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the non-viral RNA delivery systems field and establish meaningful business relationships to pursue for the rest of the conference.

11:30 am StealthX, a Non-Viral Exosome Delivery Platform for Future RNA Therapeutics

  • Minghao Sun Vice President & Head of Research & Product Development, Capricor Therapeutics

Synopsis

  • Showcasing exosome production, characterization, and manufacturing for successful reproducibility of exosome-based delivery vehicles
  • Uncovering the potential of exosomes to deliver RNA-based therapeutics effectively to the target of interest
  • Targeted delivery of ASO to skeleton muscle by exosome carrying a targeting moiety

12:00 pm ARMMs: A Non-Viral Delivery Platform for RNA Delivery with Engineerable Tropism

Synopsis

  • Introducing ARRDC1-mediated microvesicle (ARMM) biology and how it can be coopted to generate a non-viral delivery platform for macromolecular therapeutics with excellent prospects for redosability and safety
  • Demonstrating how modification of ARRDC1 allows loading of therapeutic RNAs into ARMMs for cellular delivery
  • Showcasing how engineering enables alteration of ARMMs surface proteins and fusogens to direct payloads to cells and tissues of therapeutic interest

12:30 pm Unlocking Novel Peptide Delivery Platforms for More Selective RNA Delivery to Cells Outside the Liver

Synopsis

  • Rational design of a peptide-based delivery system to overcome hepatic accumulations and to selectively target diseased tissues
  • Unlocking new RNA-based therapeutic platform that leverages novel peptide technology capable of targeting and systemically delivering therapeutic RNA and gene editing machinery into the pathological cell to combat or prevent disease
  • Demonstrating efficient mRNA delivery through systemic administration to rescue tumor suppressor functions as a potential therapeutic approach in cancers

1:00 pm Lunch & Networking

Unleashing Novel LNP Chemistry & Characterization to Optimize Formulation & Reduce Toxicity for Ensuring Safe RNA Therapeutic Delivery

2:00 pm Quantitative Nanoparticle Characterization with Flow NanoAnalyzer: Understanding Your Particles & Payload

Synopsis

  • Learn how the unique features of the Flow NanoAnalyzer enable it to detect and chatacterize single nanoparticles and quanitify their payloads
  • Understand how scientists are using NanoFCM methods and data to optimize formulation and processing conditions to create safe and effective new medicines

2:15 pm The Development of scLNP for Extrahepatic RNA Delivery

  • Qi-Ying Hu Chief Executive Officer, Corti Therapeutics

Synopsis

  • Showcasing an overview of Corti’s scLNP platform
  • Highlighting a case study example of scLNP enabled selective delivery of RNA to disease relevant cells
  • Illustrating the immunological considerations of non-viral delivery system and the feature of scLNPs

2:45 pm In Vivo Delivery of RNA by Targeted Lipid Nanoparticles (tLNP) to Hematopoietic Stem Cells in Humanized Mice & Non-Human Primates

Synopsis

  • Showcasing strategies for in vivo RNA extrahepatic delivery
  • Uncovering strategies to conjugate targeting ligands to LNPs to enable targeted and specific delivery
  • Outlining LNP compositions to reduce toxicity and enable redosability

3:15 pm Afternoon Networking Break & Scientific Poster Session

Synopsis

Contribute to the conversation and share your cutting-edge research with your fellow RNA community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Overcoming the Challenge of Endosomal Escape by Employment of Enhancer Compounds to Improve RNA Payload Delivery

3:45 pm Improving Targeted Endosomal Escape through Sapreme’s Endosomal Escape Enhancer Platform for More Potent & Durable Therapeutics

  • Miriam Bujny Chief Development Officer, Sapreme Technologies

Synopsis

• Harnessing developable and conjugatable compounds to improve delivery of different RNA payloads through improved endosomal escape

• Showcasing preclinical proof of concept for enhancing endosomal escape through this unique enhancer platform for more potent therapeutics

• Demonstrating how to conjugate this enhancer platform to targeting ligands for extra hepatic delivery

4:15 pm Stabilization & Enzymatically Gated mRNA Expression Using Nucleic Acid Nanocapsules for Enhancing Endosomal Escape

Synopsis

• Describing a novel formulation that enables room temperature stabilization of mRNA

• Showcasing how this formulation can target expression of mRNA both in vitro and in vivo using enzyme-gated release mechanisms

• Leveraging how this formulation can be paired with aptamers to enable receptor targeted delivery of mRNA and enhance endosomal escape

4:45 pm Chair’s Closing Remarks

5:00 pm End of Conference Day One